论文部分内容阅读
目的评价新一代氟喹诺酮类药物莫西沙星对耐多药肺结核病(MDR-PTB)的治疗作用。方法132例MDR-PTB患者随机分为2组:治疗组(I组)用莫西沙星0.4g,每日1次;对照组(II组)用左氧氟沙星0.4g,每日1次,疗程12月,同时辅以其他抗痨药物治疗,126例完成疗程。结果治疗组痰菌阴转率明显高于对照组(P<0.05),影像吸收率、副作用2组间差异无显著性(P>0.05)。结论莫西沙星是一种安全、有效的抗MDR-PTB药物。
Objective To evaluate the therapeutic effect of a new generation of fluoroquinolone moxifloxacin on multidrug-resistant pulmonary tuberculosis (MDR-PTB). Methods 132 patients with MDR-PTB were randomly divided into two groups: treatment group (group I) with moxifloxacin 0.4g once daily; control group (group II) with levofloxacin 0.4g once daily for 12 months , Supplemented by other anti-tuberculosis drugs, 126 cases completed the course of treatment. Results The sputum negative conversion rate in the treatment group was significantly higher than that in the control group (P <0.05). There was no significant difference between the two groups in imaging absorptivity and side effects (P> 0.05). Conclusion Moxifloxacin is a safe and effective anti-MDR-PTB drug.